Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmatech Associates Bikash Chatterjee And Chat Kwan On China's Shift To A Global Standard With New GMP Guidelines: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Headquartered in the San Francisco Bay Area, Pharmatech Associates provides business consulting services in the pharmaceutical, biotech and medical device manufacturing sectors. The company recently held two training programs on the new Chinese Good Manufacturing Practice guidelines in Shanghai. During its Dec. 11 training program, Bikash Chatterjee, the company's president and Chat Kwan, Pharmatech's China president, sat down with PharmAsia News' Shanghai bureau to talk about how the new Chinese GMP guidelines will affect the industry in China and abroad.

You may also be interested in...



China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

Multinational pharmas operating in China will need to review their manufacturing practices comprehensively to ensure full compliance because China's GMP 2010 standards contain numerous unique requirements that are different from the U.S. and ICH/EU GMPs.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel